Bristol-Myers Squibb (BMY), Innate Pharma SA Announce Encouraging Data from lirilumab and Opdivo Phase 1/2 in SCCHN Cohort
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) and Innate Pharma SA announced an interim efficacy analysis from a Phase 1/2 study of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
